Bright Minds Announces Proposed Share Consolidation
22. Juni 2023 06:50 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, June 22, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on...
Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202
19. April 2023 06:50 ET
|
Bright Minds Biosciences
-- BMB-202 is a highly selective 5-HT2A agonist that exhibits a more than 30-fold selectivity over 5-HT2C and more than 500-fold selectivity over 5-HT2B -- -- BMB-202 is the first clinical...
Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research
10. April 2023 06:50 ET
|
Bright Minds Biosciences
— Presentation entitled "BMB-101: A selective 5-HT2C agonist in clinical trials with therapeutic utility" — — First-in-human Phase 1 trial for lead program, BMB-101, is underway in Australia — ...
Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023
27. Februar 2023 06:50 ET
|
Bright Minds Biosciences
-- First-in-human Phase 1 trial for lead program, BMB-101, a highly selective 5-HT2C agonist, is underway in Australia -- -- Company has transitioned from a discovery to a development organization – ...
Bright Minds Biosciences Announces Non-Executive Director Appointment
17. Februar 2023 06:50 ET
|
Bright Minds Biosciences
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES VANCOUVER, British...
Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements
08. Februar 2023 16:05 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”) announces that it has received a letter (the...
Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
27. Januar 2023 16:05 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”) announces that it has received a notification...
Bright Minds Biosciences Announces Resignation of Board Member
09. Januar 2023 16:05 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on...
Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement
02. Dezember 2022 19:07 ET
|
Bright Minds Biosciences
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British...
Bright Minds Biosciences Announces Non-Brokered Private Placement
28. November 2022 06:50 ET
|
Bright Minds Biosciences
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British...